BiotechTube

Cysteamine Bitartrate

Phase 2Terminated
0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Mitochondrial Diseases

Conditions

Mitochondrial Diseases

Trial Timeline

May 19, 2015 → Mar 6, 2017

NCT ID
NCT02473445

About Cysteamine Bitartrate

Cysteamine Bitartrate is a phase 2 stage product being developed by Amgen for Mitochondrial Diseases. The current trial status is terminated. This product is registered under clinical trial identifier NCT02473445. Target conditions include Mitochondrial Diseases.

What happened to similar drugs?

0 of 1 similar drugs in Mitochondrial Diseases were approved

Approved (0) Terminated (0) Active (1)
🔄VatiquinonePTC TherapeuticsPhase 3

Hype Score Breakdown

Clinical
12
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT02473445Phase 2Terminated
NCT02023866Phase 2Completed

Competing Products

13 competing products in Mitochondrial Diseases

See all competitors
ProductCompanyStageHype Score
REN001OnKure TherapeuticsPhase 1
11
Mavodelpar + PlaceboOnKure TherapeuticsPhase 2
25
REN001OnKure TherapeuticsPhase 2/3
20
Bocidelpar + PlaceboAstellas PharmaPhase 2
27
Omaveloxolone capsules, 2.5 mg + omaveloxolone capsules, 5 mg + omaveloxolone capsules, 10 mg + Placebo capsules + omaveloxolone capsules, 20 mg + omaveloxolone capsules, 40 mg + omaveloxolone capsules, 80 mg + omaveloxolone capsules, 160 mgAbbViePhase 2
35
Cysteamine BitartrateAmgenPhase 2
35
VatiquinonePTC TherapeuticsPhase 2/3
27
EPI-743PTC TherapeuticsPre-clinical
23
RG2133 (2',3',5'-tri-O-acetyluridine)RepligenPhase 1
18
VatiquinonePTC TherapeuticsPre-clinical
27
VatiquinonePTC TherapeuticsPhase 3
37
Oral administration of 100 mg KH176 twice dailyCertaraPhase 2
29
Sonlicromanol + PlaceboCertaraPhase 2
33